Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2026)
Quarterly results put Liabilities and Shareholders Equity at $422.9 million for Q1 2026, up 22.97% from a year ago — trailing twelve months through Mar 2026 was $1.2 billion (up 26.89% YoY), and the annual figure for FY2025 was $232.5 million, up 23.26%.
Solid Biosciences has reported Liabilities and Shareholders Equity over the past 10 years, most recently at $422.9 million for Q1 2026.
- Liabilities and Shareholders Equity reached $422.9 million in Q1 2026 per SLDB's latest filing, up from $232.5 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $422.9 million in Q1 2026 and bottomed at $164.9 million in Q4 2023.
- Median Liabilities and Shareholders Equity over the past 5 years was $229.6 million (2023), compared with a mean of $241.6 million.
- The largest annual shift saw Liabilities and Shareholders Equity crashed 36.62% in 2023 before it skyrocketed 38.29% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $260.3 million in 2022, then crashed by 36.62% to $164.9 million in 2023, then grew by 14.38% to $188.7 million in 2024, then rose by 23.26% to $232.5 million in 2025, then skyrocketed by 81.86% to $422.9 million in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for SLDB at $422.9 million in Q1 2026, $232.5 million in Q4 2025, and $273.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 422.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 422.89 Mn |
| Dec 31, 2025 | 232.54 Mn |
| Sep 30, 2025 | 273.91 Mn |
| Jun 30, 2025 | 308.29 Mn |
| Mar 31, 2025 | 343.90 Mn |
| Dec 31, 2024 | 188.66 Mn |
| Sep 30, 2024 | 211.83 Mn |
| Jun 30, 2024 | 230.98 Mn |
| Mar 31, 2024 | 248.69 Mn |
| Dec 31, 2023 | 164.94 Mn |
| Sep 30, 2023 | 184.73 Mn |
| Jun 30, 2023 | 204.72 Mn |
| Mar 31, 2023 | 229.59 Mn |
| Dec 31, 2022 | 260.25 Mn |
| Sep 30, 2022 | 184.47 Mn |
| Jun 30, 2022 | 208.50 Mn |
| Mar 31, 2022 | 207.56 Mn |
| Dec 31, 2021 | 232.38 Mn |
| Sep 30, 2021 | 248.99 Mn |
| Jun 30, 2021 | 265.86 Mn |
| Mar 31, 2021 | 285.28 Mn |
| Dec 31, 2020 | 171.17 Mn |
| Sep 30, 2020 | 40.52 Mn |
| Jun 30, 2020 | 57.96 Mn |
| Mar 31, 2020 | 73.96 Mn |
| Dec 31, 2019 | 103.47 Mn |
| Sep 30, 2019 | 130.93 Mn |
| Jun 30, 2019 | 96.30 Mn |
| Mar 31, 2019 | 120.23 Mn |
| Dec 31, 2018 | 139.60 Mn |
| Sep 30, 2018 | 156.81 Mn |
| Jun 30, 2018 | 171.47 Mn |
| Mar 31, 2018 | 189.24 Mn |
| Dec 31, 2017 | 76.19 Mn |